3,555 Shares in AstraZeneca PLC (NASDAQ:AZN) Bought by Wolf Group Capital Advisors

Wolf Group Capital Advisors acquired a new position in AstraZeneca PLC (NASDAQ:AZN - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 3,555 shares of the company's stock, valued at approximately $261,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Banque Transatlantique SA purchased a new stake in shares of AstraZeneca during the 4th quarter valued at about $26,000. Confluence Investment Management LLC purchased a new position in shares of AstraZeneca during the first quarter valued at approximately $27,000. Mascagni Wealth Management Inc. bought a new position in AstraZeneca during the fourth quarter valued at approximately $29,000. FNY Investment Advisers LLC purchased a new stake in AstraZeneca in the first quarter worth approximately $29,000. Finally, Highline Wealth Partners LLC boosted its holdings in AstraZeneca by 447.4% in the first quarter. Highline Wealth Partners LLC now owns 416 shares of the company's stock worth $31,000 after purchasing an additional 340 shares during the last quarter. 20.35% of the stock is owned by institutional investors.

AstraZeneca Stock Performance

NASDAQ:AZN traded down $0.21 on Thursday, hitting $70.76. The stock had a trading volume of 3,370,917 shares, compared to its average volume of 5,202,526. The business's 50-day simple moving average is $70.15 and its two-hundred day simple moving average is $70.36. The stock has a market cap of $219.45 billion, a price-to-earnings ratio of 28.42, a price-to-earnings-growth ratio of 1.30 and a beta of 0.38. AstraZeneca PLC has a 52-week low of $61.24 and a 52-week high of $87.68. The company has a quick ratio of 0.70, a current ratio of 0.90 and a debt-to-equity ratio of 0.65.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.14. The firm had revenue of $13.59 billion for the quarter, compared to analysts' expectations of $13.71 billion. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The business's quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.06 EPS. As a group, research analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Analysts Set New Price Targets

Separately, BNP Paribas assumed coverage on shares of AstraZeneca in a research note on Tuesday, April 15th. They set an "outperform" rating and a $75.00 target price for the company. One analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $85.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.